Literature DB >> 9460926

Neutralization of primary and T-cell line adapted isolates of human immunodeficiency virus type 1: role of V3-specific antibodies.

S Beddows1, S Louisirirotchanakul, R Cheingsong-Popov, P J Easterbrook, P Simmonds, J Weber.   

Abstract

The role of the third variable domain (V3) of gp120 in the neutralization of primary and T-cell line adapted (TCLA) strains of human immunodeficiency virus type 1 (HIV-1) by serum from HIV-1-infected individuals was investigated. A primary virus isolate, M2424/4, when adapted to H9 cells, was more sensitive to neutralization on MT2 cells than the same stock passaged in PBMC. Neutralization of the PBMC-passaged stock by V3-specific MAbs was abrogated by addition of V3 (MN) peptide. However, exogenous V3 (MN) peptide failed to reduce the neutralization of this isolate on PBMC, or MT2 cells, by high titre anti-HIV-1 polyclonal human sera in contrast to the extensive reduction of neutralization by the same sera on MT2 cells using the prototype MN strain (4- to > or = 24-fold) and the TCLA M2424/H9 isolate (2- to 8-fold). These results indicate that the neutralization of primary virus isolates by serum from HIV-1-infected individuals is not significantly mediated by V3-specific antibodies.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9460926     DOI: 10.1099/0022-1317-79-1-77

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  16 in total

Review 1.  Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development.

Authors:  J P Moore; P W Parren; D R Burton
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

2.  Induction of antibodies in guinea pigs and rhesus monkeys against the human immunodeficiency virus type 1 envelope: neutralization of nonpathogenic and pathogenic primary isolate simian/human immunodeficiency virus strains.

Authors:  H X Liao; B Etemad-Moghadam; D C Montefiori; Y Sun; J Sodroski; R M Scearce; R W Doms; J R Thomasch; S Robinson; N L Letvin; B F Haynes
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

3.  Induction and characterization of neutralizing antibodies against a human immunodeficiency virus type 1 primary isolate.

Authors:  C H Chen; L Jin; C Zhu; S Holz-Smith; T J Matthews
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

4.  Cross-subtype neutralizing antibodies induced in baboons by a subtype E gp120 immunogen based on an R5 primary human immunodeficiency virus type 1 envelope.

Authors:  T C VanCott; J R Mascola; L D Loomis-Price; F Sinangil; N Zitomersky; J McNeil; M L Robb; D L Birx; S Barnett
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

5.  Differential susceptibility of quiescent CD4+ lymphocytes to syncytial-inducing and non-syncytial-inducing isolates of HIV-1.

Authors:  P Auewarakul; S Louisirirotchanakul; S Srisurapanon; R Phonarknguen; R Sutthent
Journal:  Int J Hematol       Date:  2001-04       Impact factor: 2.490

6.  Characterization and Implementation of a Diverse Simian Immunodeficiency Virus SIVsm Envelope Panel in the Assessment of Neutralizing Antibody Breadth Elicited in Rhesus Macaques by Multimodal Vaccines Expressing the SIVmac239 Envelope.

Authors:  Katie M Kilgore; Megan K Murphy; Samantha L Burton; Katherine S Wetzel; S Abigail Smith; Peng Xiao; Sharmila Reddy; Nicholas Francella; Donald L Sodora; Guido Silvestri; Kelly S Cole; Francois Villinger; James E Robinson; Bali Pulendran; Eric Hunter; Ronald G Collman; Rama R Amara; Cynthia A Derdeyn
Journal:  J Virol       Date:  2015-05-27       Impact factor: 5.103

7.  Antibody-mediated neutralization of primary human immunodeficiency virus type 1 isolates: investigation of the mechanism of inhibition.

Authors:  C Spenlehauer; A Kirn; A M Aubertin; C Moog
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

8.  Phenotypic Correlates of HIV-1 Macrophage Tropism.

Authors:  Kathryn T Arrildt; Celia C LaBranche; Sarah B Joseph; Elena N Dukhovlinova; William D Graham; Li-Hua Ping; Gretja Schnell; Christa B Sturdevant; Laura P Kincer; Macpherson Mallewa; Robert S Heyderman; Annelies Van Rie; Myron S Cohen; Serena Spudich; Richard W Price; David C Montefiori; Ronald Swanstrom
Journal:  J Virol       Date:  2015-09-02       Impact factor: 5.103

9.  HIV-1 envelope proteins and V1/V2 domain scaffolds with mannose-5 to improve the magnitude and quality of protective antibody responses to HIV-1.

Authors:  Javier F Morales; Trevor J Morin; Bin Yu; Gwen P Tatsuno; Sara M O'Rourke; Richard Theolis; Kathryn A Mesa; Phillip W Berman
Journal:  J Biol Chem       Date:  2014-07-25       Impact factor: 5.157

10.  Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades.

Authors:  Miroslaw K Gorny; Constance Williams; Barbara Volsky; Kathy Revesz; Sandra Cohen; Victoria R Polonis; William J Honnen; Samuel C Kayman; Chavdar Krachmarov; Abraham Pinter; Susan Zolla-Pazner
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.